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Summary Globally, young infant mortality comprises 40% of the estimated 10.8million child
deaths annually. Almost all (99%) of these deaths arise in low- and middle-income countries
(LMICs). Achievement of the Millennium Development Goal for child survival, however, requires
a signiﬁcant improvement in the management of infections in young infants. We have reviewed
current evidence from LMICs on one major cause of young infant mortality, severe infec-
tion, and have described the range of pathogens, reported antibiotic susceptibility and value
of clinical signs in identifying severe bacterial illness. Evidence from the reviewed studies
appears to show that common pathogens in young infant infections change over time and
vary within and across settings. However, there are few good, large studies outside major
urban settings and many reports describe infections of babies born in hospital when most
young infant infections probably occur in the majority born at home. Yet what knowledge
there is can aid in instituting prompt and appropriate therapy, and perhaps thus minimize
the emergence of multidrug-resistant bacteraemia, a major threat at least in hospital set-
tings. Improved country level data on pattern of microorganisms, resistance and antibiotic use
are required to help reduce mortality through development of local, evidence-based clinical
guidelines.
© 2007 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights
reserved.1. Introduction
Despite overall improvement in the health of children world-
wide, mortality among young infants less than 2 months old
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doi:10.1016/j.trstmh.2007.05.005emains high (Bhutta et al., 2003). Young infant mortality
omprises 40% of the estimated 10.8 million child deaths
orldwide annually (Duke et al., 2005). About 4 million
f these deaths (more than 10 000 deaths per day) occur
uring the neonatal period, with severe infections being
direct cause in 26% of them (Lawn et al., 2005). Nearly
ll of these deaths (99%) arise in low- and middle-income
ountries (LMICs). Thus, in LMICs, the fourth Millennium
evelopment Goal, which aspires to a global target, by 2015,
f reducing the under ﬁve mortality by two-thirds, cannot be
e and Hygiene. Published by Elsevier Ltd. All rights reserved.
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Table 1 Clinical questions
1. What are the major bacterial pathogens in the
neonatal/young infant age group?
2. What is known about antibiotic sensitivities/resistance
in common pathogens in young infants?
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a3. What clinical signs best identify severe illness in young
infants?
chieved without substantial reductions in neonatal deaths
Lawn et al., 2005; Zupan, 2005).
Addressing young infant mortality attributable to infec-
ion calls for a continuum of care, including, importantly,
etter prevention, improved recognition of severe illness
nd appropriate case management. The latter should take
ccount of the site at which the infections are acquired (hos-
ital or community) (Zaidi et al., 2005) and their time of
nset (early or late) (Vergnano et al., 2005). Both these fac-
ors may have implications for the choice of empiric antibi-
tic therapy. In addition, quick identiﬁcation and referral
f the severely sick infants from the home or primary care
etting may be life-saving. We therefore summarized cur-
ent evidence on the aetiology, antibiotic susceptibility and
linical signs in young infant sepsis that might support the
ntroduction of evidence-based practice guidelines.
. Materials and methods
.1. Clinical questions
e conducted literature searches to answer clinical ques-
ions on the aetiology, antibiotic susceptibility and clinical
igns in young infant sepsis (Table 1). We aimed to include
nly recent data from the LMICs.
.2. Search strategy
otential articles for inclusion were identiﬁed by direct
earches of MEDLINE via PubMed by use of clinical queries
1990 to March 2006) (Haynes and Wilcynski, 2004; Montori
t al., 2005) and without language restriction. We used the
ollowing combinations of search terms:
Aetiology, broad sensitive search: neonatal sepsis AND
(bacterial pathogens OR bacterial isolates)
Therapy, broad sensitive search: neonatal sepsis AND
(bacterial susceptibility OR antibiotic sensitivity OR
antibiotic resistance)
Diagnosis, narrow speciﬁc search: (sepsis OR severe ill-
ness) AND (signs OR predictors) AND (neonates OR infants)
To ensure a more comprehensive review, we conducted
upplementary searches in the Cochrane Library (Issue 2,
006), bibliographies of retrieved articles and reference col-
ection of experts in the ﬁeld (Figure 1)..3. Study selection and quality assessment
he titles and abstracts of the retrieved articles were read
y two independent reviewers. Studies from LMICs meet-
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eFigure 1 Study identiﬁcation and selection process.
ng the following inclusion criteria were selected for a more
etailed review: those with primary data on aetiological
gents, antibiotic sensitivity/resistance and clinical signs
redicting severe illness in infants less than 2 months. For
tudies of clinical signs, the search was expanded to include
hose from all countries. Existing high quality reviews were
ot replicated, but individual studies included in these
eviews were re-examined, if required, to answer our par-
icular clinical questions. Articles were not excluded if the
tudies enrolled some children outside the 0—2 months age
ange. However, articles on biochemical markers of severe
llness were excluded, as such laboratory investigations are
arely available in LMICs.
The methodological quality of the studies was assessed
sing the Oxford Centre for Evidence-Based Medicine lev-
ls of evidence, which ranks the validity of evidence in a
ierarchy of levels, with systematic reviews (SRs) as level
(strong evidence) and expert opinions as level 5 (weak
vidence) (Phillips et al., 1988).
. Results
.1. Description of included studies
verall, we identiﬁed 25 articles that met the preset
nclusion criteria: 14 of the articles were on aetiology
Adejuyigbe et al., 2004; Aurangzeb and Hameed, 2003;
ell et al., 2005; Berkley et al., 2005; Chacko and Sohi,
005; Jiang et al., 2004; Kaushik et al., 1998; Laving et al.,
003; Milledge et al., 2005; Mokuolu et al., 2002; Musoke
nd Revathi, 2000; Rahman et al., 2002; Waheed et al.,
003; WHO Young Infants Study Group, 1999); 10 had data on
ntibiotic sensitivities/resistances (Adejuyigbe et al., 2004;
urangzeb and Hameed, 2003; Berkley et al., 2005; Duke et
l., 2005; Laving et al., 2003; Milledge et al., 2005; Mokuolu
t al., 2002; Musoke and Revathi, 2000; Rahman et al., 2002;
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WHO Young Infants Study Group, 1999); eight assessed clin-
ical signs of serious infections in young infants (Bang et al.,
2005; Duke et al., 2005; English et al., 2003, 2004; Gupta et
al., 2000; Hewson et al., 2000; Kalter et al., 1997; Weber
et al., 2003); and three examined the Baby Check scoring
system (Chandran et al., 1998; Morley et al., 1994; Twite
and Morley, 1995). Ten articles (Adejuyigbe et al., 2004;
Aurangzeb and Hameed, 2003; Berkley et al., 2005; Duke et
al., 2005; Laving et al., 2003; Milledge et al., 2005; Mokuolu
et al., 2002; Musoke and Revathi, 2000; Rahman et al.,
2002; WHO Young Infants Study Group, 1999) examined more
than one aspect of the clinical questions and are therefore
included more than once in this summary. Seventeen studies
were prospective (Adejuyigbe et al., 2004; Aurangzeb and
Hameed, 2003; Berkley et al., 2005; Chacko and Sohi, 2005;
Chandran et al., 1998; Duke et al., 2005; English et al., 2003,
2004; Gupta et al., 2000; Hewson et al., 2000; Kalter et al.,
1997; Weber et al., 2003; Kaushik et al., 1998; Morley et al.,
1994; Rahman et al., 2002; Twite and Morley, 1995; WHO
Young Infants Study Group, 1999); six were retrospective
(Bang et al., 2005; Bell et al., 2005; Clark et al., 2006; Jiang
et al., 2004; Milledge et al., 2005; Mokuolu et al., 2002);
two were descriptive (Laving et al., 2003; Waheed et al.,
2003); and one was partly prospective and partly retrospec-
tive (Musoke and Revathi, 2000). Four studies included some
infants outside the 0—2 months age group (Berkley et al.,
2005; English et al., 2003; Hewson et al., 2000; WHO Young
Infants Study Group, 1999). The ﬁndings of the studies on
aetiology and antibiotic sensitivities/resistances were cate-
gorized by setting (hospital-acquired, community-acquired,
mixed site) and time of onset (early onset, late onset).
3.2. Deﬁnitions
Severe illness was deﬁned as one of: a positive blood culture
or cerebrospinal ﬂuid culture; a chest X-ray with consol-
idation or an oxygen saturation of <90% (English et al.,
2003, 2004; Hewson et al., 2000; Weber et al., 2003; WHO
Young Infants Study Group, 1999); death (English et al.,
2004; Weber et al., 2003); or need for ‘signiﬁcant inpa-
tient treatment’ (ﬂuid therapy, parental antibiotics, oxygen,
surgery) (Hewson et al., 2000). Hospital-acquired infection
was deﬁned as any infection associated with birth or a stay in
a hospital, while community- acquired infection was deﬁned
as any infection associated with probable home birth. Data
described as from mixed sites are from studies where it
is either not possible to tell whether pathogens reported
to be responsible for young infant sepsis are hospital- or
community-acquired or the report covers a truly mixed pop-
ulation with no stratiﬁcation by likely origin of infection.
Relative consistency in the applied deﬁnition is imperative
for the comparison of data in the included studies.
3.3. Bacterial aetiology (Table 2)
Fourteen articles were reviewed to determine the spec-
trum of bacterial pathogens responsible for young infant
infections and to compare these pathogens across settings.
In one hospital-based study, Escherichia coli (78%; 52/67)
was the major pathogen (Aurangzeb and Hameed, 2003).
Data on community-acquired sepsis were scarce, however,
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ith only two studies reported (Berkley et al., 2005; WHO
oung Infants Study Group, 1999). The spectrum of organ-
sms reported in these studies differ, with E. coli and
roup B Streptococcus (GBS) dominating in one Kenyan
tudy (Berkley et al., 2005) and Streptococcus pneumoniae,
taphylococcus aureus, E. coli and Salmonella predominat-
ng in the other (WHO Young Infants Study Group, 1999).
Eight studies present mixed-site data on young infant
nfections (Adejuyigbe et al., 2004; Kaushik et al., 1998;
aving et al., 2003; Milledge et al., 2005; Mokuolu et al.,
002; Musoke and Revathi, 2000; Rahman et al., 2002;
aheed et al., 2003). Summarizing these data, gram-
egative organisms were isolated more frequently than
ram-positive organisms, with E. coli (Kaushik et al., 1998;
ahman et al., 2002), Klebsiella (Kaushik et al., 1998; Laving
t al., 2003; Mokuolu et al., 2002; Musoke and Revathi,
000), GBS (Laving et al., 2003; Milledge et al., 2005) and
taph. aureus (Adejuyigbe et al., 2004; Kaushik et al., 1998;
illedge et al., 2005; Mokuolu et al., 2002; Waheed et al.,
003) being the most frequently reported isolates.
.3.1. Bacterial pathogens causing early- and late-onset
epsis
arly-onset sepsis (EOS) is mainly acquired before delivery
vertical transmission from organisms that infect/colonize
he maternal genital tract or via the placenta after mater-
al bacteraemia) or during delivery as the baby passes
hrough the birth canal. By contrast, late-onset sepsis (LOS)
s mostly acquired after delivery from hospital or commu-
ity sources. This classiﬁcation is thought to be helpful
ecause of probable differences in the pathophysiology and
athogens associated with EOS and LOS. The clinical rel-
vance of data stratiﬁed by time of onset of sepsis is,
owever, limited by wide variations in the age limits in the
eﬁnitions [for EOS, 0—72 h (Chacko and Sohi, 2005; Kaushik
t al., 1998) or 0—7 d (Aurangzeb and Hameed, 2003; Bell et
l., 2005; Jiang et al., 2004; Waheed et al., 2003); for LOS,
72 h (Chacko and Sohi, 2005; Kaushik et al., 1998) or >7 d
Aurangzeb and Hameed, 2003; Bell et al., 2005; Jiang et al.,
004; Waheed et al., 2003)]. It was not possible to standard-
ze the above deﬁnitions, so the original study deﬁnitions are
etained.
.3.2. Hospital-acquired EOS and LOS
wo studies (Aurangzeb and Hameed, 2003; Chacko and Sohi,
005) presented data on hospital-acquired EOS and LOS.
enerally, gram-negative organisms were isolated signiﬁ-
antly more frequently than gram-positives, with Klebsiella,
seudomonas, E. coli and Staph. aureus predominating in
oth EOS and LOS. However, the similarity in the spectrum of
rganisms causing EOS and LOS is confounded by differences
n the age limits in the studies included in the review.
.3.3. Mixed-site EOS and LOS
ata from ﬁve studies (Bell et al., 2005; Jiang et al., 2004;
aushik et al., 1998; Mokuolu et al., 2002; Waheed et al.,
003) on mixed-site EOS and LOS show that E. coli and GBS
re the common pathogens in EOS. However, the pathogens
nvolved in LOS are varied and include E. coli (Bell et al.,
005; Jiang et al., 2004; Waheed et al., 2003), Staph.
ureus (Aurangzeb and Hameed, 2003; Mokuolu et al., 2002)
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Table 2 Bacterial pathogens
Bacterial isolate 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Total
Gram positive Staph. aureus 87 (11.1) 11 (7.8) 16 (9.3) 2 (13.3) 153 (61.2) 44 (12.5) — — 23 (9.9) 18 (29.5) 9 (7.4) 296 (29.5) 29 (17.8) — 688 (20.1)
CONSa — 13 (9.2) — — 47 (18.8) 71 (20.1) — — — 15 (24.6) — — — — 146 (4.3)
Staph.
epidermidis
— — — — — — — — 21 (9) — 19 (15.7) — — 4 (10.0) 44 (1.3)
Group B
streptococci
136 (17.4) 15 (10.6) 20 (11.6) — — 18 (5.1) — 4 (26.7) — — — — 3 (1.8) — 196 (5.7)
Group A
streptococci
56 (7.1) — 13 (7.5) — — — — — — — — — — — 69 (2.0)
Other
streptococci
— 13 (9.2) — 1 (6.7) — — — — — — — — — — 14 (0.4)
S. pneumoniae 79 (10.1) — 13 (7.5) — — — — — — — — — 37 (22.7) — 129 (3.8)
Other 72 (9.2) — 8 (4.6) — 4 (1.6) 27 (7.5) 4 (5.9) — 2 (0.86) 2 (3.3) 4 (3.3) — 28 (17.2) 16 (40.0) 167 (4.9)
Gram
neg-
a-
tive
Escherichia coli 67 (8.6) 22 (15.6) 19 (11.0) 1 (6.7) 5 (2.0) 44 (12.5) 52 (77.6) 7 (46.7) 111 (47.5) 3 (4.9) 4 (3.3) 367 (36.6) 23 (14.1) 11 (27.5) 736 (21.5)
Pseudomonas — 4 (2.8) 9 (5.2) 9 (60.0) 6 (2.4) 20 (5.7) 6 (8.9) — 37 (15.9) 1 (1.6) — 225 (22.4) 4 (2.5) — 321 (9.4)
Klebsiella 60 (7.7) 39 (27.7) 17 (9.8) 2 (13.3) 2 (0.8) 25 (7.1) 5 (7.5) 2 (13.3) 39 (16.8) 10 (16.4) 38 (31.4) 77 (7.6) 3 (1.8) 6 (15.0) 325 (9.5)
Salmonella 110 (14.0) — 3 (1.7) — 15 (6.0) — — — — — 2 (1.7) — 14 (8.6) — 144 (4.2)
Enterobacter — 14 (9.9) — — 2 (0.8) — — — — — 19 (15.7) — 10 (6.1) 3 (7.5) 48 (1.4)
Acinetobacter — 2 (1.4) 17 (9.8) — — 26 (7.4) — — — 3 (4.9) — — 3 (1.8) — 51 (1.5)
Proteus — 3 (2.1) — — 13 (5.2) — — — — — — 38 (3.8) — — 54 (1.6)
Citrobacter — 2 (1.4) — — 3 (1.2) — — — — — — — — — 5 (0.1)
Other 117 (14.9) 3 (2.1) 38 (22.0) — — 61 (17.3) — — — 9 (14.8) 26 (21.5) — 5 (3.1) — 259 (7.6)
Other pathogens — — — — — 17 (4.8) — 2 (13.3) — — — — 4 (2.5) — 23 (0.7)
Total 784 141 173 15 250 353 67 15 233 61 121 1003 163 40 3419
1: Milledge et al. (2005); 2: Bell et al. (2005); 3: Berkley et al. (2005); 4: Chacko and Sohi (2005); 5: Adejuyigbe et al. (2004); 6: Jiang et al. (2004); 7: Aurangzeb and Hameed (2003); 8:
Laving et al. (2003); 9: Waheed et al. (2003); 10: Mokuolu et al. (2002); 11: Musoke et al. (2002); 12: Rahman et al. (2002); 13: WHO Young Infants Study Group (1999); 14: Kaushik et al.
(1998). Data are no. (%) of culture-conﬁrmed isolates. All the studies were of level 4 evidence.
a Coagulase-negative Staphylococcus.
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and coagulase-negative Staphylococcus (CONS) (Jiang et al.,
2004; Mokuolu et al., 2002).
3.4. Antimicrobial susceptibility (Table 3)
In many developing countries, antimicrobial sensitivity
and resistance testing, a necessary component of rational
antimicrobial prescribing, is uncommon and may be unre-
liable in routine clinical settings. The gold standard for
assessing antimicrobial susceptibility is determination of the
minimum inhibitory concentration (MIC). Classically, this is
undertaken using a labour-intensive serial dilution tech-
nique, although more recently an accurate quantitative and
rapid technique (E-test) has been successfully used (Berkley
et al., 2005). Among the studies reviewed, most report
resistance rates based on simple disc diffusion, a technique
that provides an ‘all-or-none’ classiﬁcation that will not,
especially in the case of penicillin class drugs, provide any
indication of whether resistance is of an intermediate or high
grade, which can be clinically very important. We therefore
summarize the results of studies on antibiotic treatment
regimens and susceptibilities, including the susceptibility
testing method (Table 2), by settings.
3.4.1. Community-based studies
In one Kenyan study on community-acquired invasive bacte-
rial disease, in-vitro antimicrobial susceptibilities among all
the bacteria were as follows: amoxycillin/ampicillin (55%);
benzylpenicillin alone (31%); either penicillin or gentamicin
(88%); either ampicillin or gentamicin (97%); and either peni-
cillin or chloramphenicol (82%) (Berkley et al., 2005). These
results support the ﬁndings of the multicentre WHO study
on serious infections in young infants, which suggest initial
therapy of neonatal sepsis with ampicillin and gentamicin
(WHO Young Infants Study Group, 1999). This regimen, how-
ever, provides only modest cover for Staph. aureus. Thus,
in suspected staphylococcal (skin) infection, initial ther-
apy should include cloxacillin, but if this is used to replace
ampicillin, the reduced efﬁcacy of the combination against
gram-negative infections should be kept in mind and fail-
ure to improve within 48 h should perhaps prompt use of the
combination of cloxacillin, ampicillin and gentamicin.
3.4.2. Mixed studies
Resistance of gram-negative organisms to the empiric ﬁrst-
line antibiotics remains high: ampicillin (79.3%), amoxicillin
(74.6%) and gentamicin (43.2%) (Aurangzeb and Hameed,
2003). However, this ﬁnding requires validation, given that
most of these data were collected from specialized new-
born units, where levels of in-vitro resistance to antibiotics
may be considerably higher than in smaller hospitals or
for community-acquired infection. Gentamicin resistance
among gram-negative bacteria is variable: 20% in Kenya;
24% in India; 43% in one study from Pakistan and 78—84% in
another; 66% in Papua New Guinea; and 77% in Guatemala
(Duke et al., 2005). These ﬁndings are consistent with those
of another review, which reported that resistance rates of
E. coli, Klebsiella and Pseudomonas ranged from 65 to 100%
for ampicillin and 0 to 93% for gentamicin (Vergnano et al.,
2005).
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Additional data from Malawi (Milledge et al., 2005),
enya (Laving et al., 2003) and Pakistan (Rahman et al.,
002) show that resistance rates of gram-negative organisms
o ampicillin and gentamicin remain high. By contrast, in
tudies from Nigeria (Adejuyigbe et al., 2004; Mokuolu et al.,
002) and Kenya (Musoke and Revathi, 2000), gram-negative
rganisms showed good sensitivities to gentamicin and to
mikacin, cefuroxime and third-generation cephalosporins
ceftriaxone, ceftazidime and cefotaxime) (Laving et al.,
003). The variation in resistance patterns is likely to reﬂect
emporal and geographic differences; hence the need for
ocal surveillance data to support empiric antibiotic pre-
criptions.
.5. Identiﬁcation of severe bacterial illness
.5.1. Clinical predictors
total of eight studies from India (Bang et al., 2005; Gupta
t al., 2000), Papua New Guinea (Duke et al., 2005; Weber
t al., 2003), Kenya (English et al., 2003, 2004), The Gam-
ia/The Philippines/Ethiopia (Weber et al., 2003), Australia
Hewson et al., 2000) and Bangladesh (Kalter et al., 1997)
ere reviewed to determine which clinical signs best pre-
ict severe bacterial illness (SBI) in young infants. Three of
he studies (Gupta et al., 2000; Hewson et al., 2000; Kalter
t al., 1997) evaluated the validity of previously identiﬁed
arkers of serious illness in infancy. Overall, the following
anel of signs are likely to be the most valuable in identi-
ying a young infant at risk of severe illness: cyanosis (Duke
t al., 2005; English et al., 2004; Weber et al., 2003); a
istory of feeding difﬁculty (Bang et al., 2005; Duke et al.,
005; English et al., 2003, 2004; Weber et al., 2003); breath-
ng difﬁculty (grunting) (English et al., 2004; Hewson et al.,
000; Weber et al., 2003); fast breathing (respiratory rate
60 bpm) (Bang et al., 2005; Duke et al., 2005; English et al.,
004; Weber et al., 2003); abnormal behaviour (English et
l., 2003, 2004; Weber et al., 2003); and fever/temperature
38 ◦C (Hewson et al., 2000; Weber et al., 2003).
.5.2. Baby Check
hree studies investigated the utility of the Baby Check, a
ystematic way of grading the severity of illness in infants
ounger than 6 months (Chandran et al., 1998; Morley et al.,
994; Twite and Morley, 1995). The scoring system involves
he recognition of a combination of seven symptoms and 12
igns, with the higher the total score the greater the chance
f the baby being seriously ill. In the reviewed studies,
he scores generally correlated with the grades of illness,
uggesting that the use of the Baby Check increases the
ccuracy of identifying sick infants. Furthermore, these ﬁnd-
ngs seem to be stable over different settings (Twite and
orley, 1995). However, a number of factors limit the util-
ty of the Baby Check as a tool to grade the severity of
he illness: (1) there was no laboratory- or investigation-
onﬁrmed ‘gold standard’ against which to test the accuracy
f the Baby Check; (2) the scoring system seems to be inad-
quate in cases of co-morbidity (many young sick infants
resent with multiple illnesses concurrently); and (3) the
aby Check demands a long list of values and a numerical
coring system,making it a bit impractical for primary health
are settings in LMICs. Despite these limitations, the scoring
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Table 3 Antibiotic sensitivity
Pathogen Antibiotic 1 2 3 4 5 6 Total
Escherichia
coli
Ampicillin 17/67 (25) 2/5 (40) 10/52 (19.1) — 0/2 (0) 40/367 (11) 69/528 (13.1)
Amoxycillin — 3/5 (60) 13/52 (25) — — — 16/57 (28.1)
Gentamicin 62/67 (93) 4/5 (80) 32/52 (61.5) — 3/3 (100) 78/367 (21.3) 179/494 (36.2)
Cefotaxime — — 20/52 (38.4) 72/111 (65) — 120/367 (32.6) 212/530 (40.0)
Ceftazidime — — 12/52 (23) 61/111 (55) 0/1 (0) 119/367 (32.5) 192/531 (36.2)
Ceftriaxone 8/8 (100) — 26/52 (50) — 2/2 (100) 103/367 (28) 139/429 (32.4)
Pseudomonas Ampicillin — 3/5 (60) 2/6 (33.3) — — 31/225 (13.6) 36/236 (15.3)
Amoxycillin — 2/55 (40) 2/6 (33.3) — — — 4/61 (6.6)
Gentamicin — 5/5 (100) 52/156 (33.3) — — 48/225 (21.4) 105/386 (27.2)
Cefotaxime — — 4/6 (66.6) 19/37 (50) — 61/225 (27) 84/268 (31.3)
Ceftazidime — — 1/6 (16.6) 13/37 (35) — 98/225 (43.5) 112/268 (41.8)
Ceftriaxone — — 4/6 (66.6) — — 74/225 (33) 78/231 (33.8)
Klebsiella Ampicillin 0/60 (0) — 1/5 (20) — 1/4 (25) 27/77 (34.7) 29/146 (19.9)
Amoxycillin — 0/1 (0) 0/5 (0) — — — 0/6 (0)
Gentamicin 20/60 (33) 1/1 (100) 2/5 (40) — 6/9 (66.7) 12/77 (16) 41/152 (27.0)
Cefotaxime — — 3/5 (60) 31/39 (80) — 11/77 (14) 45/121 (37.2)
Ceftazidime — — 3/5 (60) 31/39 (80) 2/4 (50) 26/77 (33.8) 62/125 (49.6)
Ceftriaxone 4/4 (100) — 3/5 (60) — 5/6 (83.3) 14/77 (18) 26/92 (28.3)
Staph. aureus Ampicillin 74/86 (86) — 1/4 (25) — 1/6 (16.7) 178/296 (60) 254/392 (64.8)
Amoxycillin — 74/101 (73) 2/4 (50) — — — 76/105 (72.4)
Gentamicin — 87/101 (85.8) 2/4 (50) — 7/12 (58.3) 89/296 (30) 185/413 (44.8)
Cefotaxime — — 3/4 (75) 16/23 (70) — 148/296 (50) 167/323 (51.8)
Ceftazidime — — 3/4 (75) 16/23 (70) 5/7 (71.4) 109/296 (36.8) 133/330 (40.3)
Ceftriaxone — — 3/4 (75) — 6/11 (54.5) 122/296 (41.2) 131/311 (42.1)
1: Milledge et al. (2005); 2: Adejuyigbe et al. (2004); 3: Aurangzeb and Hameed (2003); 4: Waheed et al. (2003); 5: Mokuolu et al. (2002); 6: Rahman et al. (2002). Data are no. of isolates
sensitive/no. tested (% sensitive).
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system seems to be fairly accurate in identifying high-risk
infants.
4. Discussion
4.1. Summary of current evidence
The study setting has important implications in young infant
infections: most hospital-based studies even in LMICs are
conducted in neonatal intensive care units (NICUs), with
higher proportions of pre-term births, prolonged hospi-
tal stays and high antibiotic resistance rates. However,
adequate laboratory testing is not feasible in the com-
munity, with consequences of disease misclassiﬁcation in
most community-based studies. These issues notwithstand-
ing, reviewed evidence shows that causative agents of young
infant sepsis vary according to the setting within which
infection is acquired: gram-negative organisms (E. coli,
Klebsiella, Pseudomonas) predominate in hospital-acquired
infections, while gram-positive organisms (Staph. aureus,
GBS, Strep. pneumoniae, Strep. pyogenes) predominate in
community-acquired infections. Not surprisingly, common
organisms in mixed-site infections are variable, with E. coli,
Klebsiella, Staph. aureus and GBS being important organ-
isms. On the whole, E. coli, Klebsiella, Pseudomonas, Staph.
aureus and GBS are responsible for most infections across
all the settings. Causative organisms in EOS and LOS are
variable, reﬂecting differences in deﬁnitions, in population
characteristics and in predisposing factors: GBS is commonly
reported in EOS (signifying vertical transmission from the
maternal genital tract), whereas E. coli and Pseudomonas
are frequent in both EOS and LOS. These ﬁndings underscore
the need to tailor empiric antibiotic therapy according to
the site at which the infection is acquired.
Based on the available evidence, the combination of
ampicillin or penicillin and gentamicin still remains suitable
for ﬁrst-line treatment for young infant sepsis. However,
the rapid emergence of resistance to third-generation
cephalosporins (Musoke and Revathi, 2000) and recent ﬁnd-
ings from the USA that suggest that ﬁrst-line treatment with
these drugs is associated with an increased risk of mortal-
ity (Clark et al., 2006) caution against their overuse and
provide a strong rationale for improving local surveillance
on antibiotic susceptibility and outcomes to guide future
empiric therapy.
Evidence from studies that examined clinical recogni-
tion of severe illnesses suggest that any one of cyanosis,
a history of feeding difﬁculty, breathing difﬁculty (grunt-
ing), fast breathing (respiratory rate >60 bpm), chest
indrawing, abnormal behaviour/change in activity and
fever/temperature >38 ◦C seem to be sensitive, although
their speciﬁcity is modest. Unfortunately, while none of
these signs alone reliably predicts SBIs, demanding that a
young infant have two or more signs considerably reduces
sensitivity, although it does improve the positive predic-
tive value. In conclusion, currently, there seems to be
no highly sensitive and highly speciﬁc clinical screening
tool for identiﬁcation of seriously sick infants with sepsis.
At present, therefore, optimizing sensitivity and simplic-
ity of classiﬁcation to avoid potentially life-threatening
disease would suggest categorizing a young infant as at
C
E965
igh risk of SBI based on any one of the signs listed
bove.
.2. Conclusions
n most of the reported studies, it is difﬁcult to determine
hether infections were ‘maternally-acquired’ (a conse-
uence of exposure before birth or within the birth canal),
hospital-acquired’ (a consequence of any of poor deliv-
ry techniques, poor ward hygiene or prolonged stay) or
community-acquired’ (a consequence of exposure in an
ntirely community setting). Also, there were wide vari-
tions in the deﬁnitions for EOS/LOS, clinical signs and
ge distribution of ‘young’ infants: 0—28 d (Aurangzeb
nd Hameed, 2003; Bang et al., 2005; Laving et al.,
003; Mokuolu et al., 2002; Waheed et al., 2003); 0—60 d
Adejuyigbe et al., 2004; Berkley et al., 2005; Duke et al.,
005; Milledge et al., 2005; English et al., 2004; Gupta et
l., 2000; Kalter et al., 1997; Weber et al., 2003); 0—90
(English et al., 2003; WHO Young Infants Study Group,
999); 1—26 weeks (Hewson et al., 2000). Future work would
eneﬁt considerably from a clear description of the study
etting and probable source of infection and increasing use
f enhanced antibiotic susceptibility testing. Moreover, the
bserved variations in the deﬁnitions highlight the neces-
ity for a consensus deﬁnition of paediatric sepsis, to aid in
tandardization of observational studies and evaluation of
ge-speciﬁc therapeutic hypotheses in clinical trials.
A number of important knowledge gaps emerged in
his review: ﬁrst, there is a need for routine longitudinal
urveillance across settings to describe the varied pathogens
ausing young infant sepsis, as well as their changing sus-
eptibility proﬁle. Such surveillance should then direct
uture randomized controlled trials comparing clinical fail-
re rates and antibiotic regimens for suspected sepsis in
oung infants. Secondly, more rigorous ﬁeld-tested studies
re needed to evaluate various signs as predictors of SBIs
n young infants. These studies should give rise to simple,
obust clinical prediction rules that can alert mothers and
aretakers to seek care and be used in essential training
ackages for primary health care workers.
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